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Objectives: The primary aim of this study was to determine how Parkinson’s disease (PD) affects driving
performance. It also examined whether changes in driver safety were related to specific clinical disease
markers or an individual’s self rating of driving ability.
Methods: The driving performance of 25 patients with idiopathic PD and 21 age matched controls was
assessed on a standardised open road route by an occupational therapist and driving instructor, to
provide overall safety ratings and specific driving error scores.
Results: The drivers with PD were rated as significantly less safe (p,0.05) than controls, and more than
half of the drivers with PD would not have passed a state based driving test. The driver safety ratings were
more strongly related to disease duration (r=20.60) than to their on time Unified Parkinson’s Disease
Rating Scale (r=20.24). Drivers with PD made significantly more errors than the control group during
manoeuvres that involved changing lanes and lane keeping, monitoring their blind spot, reversing, car
parking, and traffic light controlled intersections. The driving instructor also had to intervene to avoid an
incident significantly more often for drivers with PD than for controls. Interestingly, driver safety ratings
were unrelated to an individual’s rating of their own driving performance, and this was the case for all
participants.
Conclusions: As a group, drivers with PD are less safe to drive than age matched controls. Standard
clinical markers cannot reliably predict driver safety. Further studies are required to ascertain whether the
identified driving difficulties can be ameliorated.
P
arkinson’s disease (PD) is a progressive neurodegenera-
tive disease that affects motor and sometimes cognitive
function, which could potentially impair driving perfor-
mance, thereby limiting mobility and independence. Few
studies have evaluated driving performance in PD. An
exception has been the potential impact of medication
induced sleep episodes on driving performance.1 However,
these studies have methodological problems,2 and sleep
episodes are arguably a less important source of driving
difficulties than those that stem directly from the disease.3
For example, in addition to the cardinal symptoms of brady-
kinesia, tremor, and rigidity, several less obvious deficits
include difficulties in movement planning,4 movement
sequences,5 and simultaneous movements,6 in addition to
subtle visual defects and impairments in shifting attentional
set.7 Therefore, it is imperative to characterise fully the impact
of PD on driving performance.
Madeley et al reported longer reaction times and reduced
steering accuracy in a driving simulator in a small sample of
patients with PD compared with controls.8 These impair-
ments were significantly related to the PD group’s Webster
scores. Lings and Dupont9 also found increased reaction times
and directional errors in PD using a simulator, but did not
find a relation between the Webster scale and driving
simulator performance. Recently Zesiewicz et al also used a
simulator to assess PD driving performance; however, the
only reported driving measure was the number of collisions,
which was higher in those with PD than in control drivers,
and was related to both the Hoehn and Yahr scale and the
Unified Parkinson’s Disease Rating Scale (UPDRS).10 Despite
the known limitations of simulators,11 all of these studies
demonstrated poorer driving skills in the individuals with PD
compared with controls.
Although no studies have dealt with state reported crash
rates for PD, Dubinsky and colleagues12 found that crashes
(self reported retrospectively over three years) were more
common in drivers with PD than in controls, and were
related both to the Hoehn and Yahr rating and to dementia
(Mini Mental State Examination; MMSE). However, the
relation between self reported crash rates and state registered
crashes has proved to be inconsistent.13
Only two studies, undertaken in Scandinavia14 and the
UK,15 have assessed the on road driving performance of
drivers with PD. Heikkila¨ et al reported that drivers with PD
were significantly less safe than controls, with 35% rated as
being unsafe to drive, and reported a low level of agreement
between safety ratings of the neurologist and the driving
instructor, compared with safety self ratings of drivers with
PD.14 A combination of slowed visual processing, levodopa
dosage, and age was shown to explain 67% of the variance in
driving test scores in drivers with PD.14 Recently, Radford et al
assessed drivers with PD on the open road, but included no
control group.15 In contrast to Heikkila¨ et al,14 they found that
only six of 33 drivers with PD were rated as unsafe, but this
discordant finding may have resulted from selection bias,
because participants were volunteers rather than a consecu-
tive patient series. The use of a control group recruited in the
same manner and from the same community groups assumes
greater importance in such situations. Like Madeley et al,8
they found a link between the Webster scale and driving
performance, although the small number of unsafe drivers in
the sample limits this finding’s validity.
Our present study investigated the effect of PD on overall
driving safety and specific aspects of driving performance on
the open road, using well established, quantitative scoring
methods. A further aim was to determine whether any
Abbreviations: MMSE, Mini Mental State Examination; PD, Parkinson’s
disease; UPDRS, Unified Parkinson’s Disease Rating Scale
See Editorial Commentary, page 159
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changes in driver safety could be predicted by clinical disease
markers or an individual’s rating of their own driving ability.
METHODS
Participants
Twenty five participants (21 men, four women) with a
diagnosis of idiopathic PD and 21 control participants (18
men, three women) in good general health, who drove at
least one day each week, performed an on road driving
assessment. All participants scored 24 or more on the
MMSE,16 and none was excluded on the basis of dementia.
All participants were community dwelling volunteers who
had attended presentations at PD support group meetings.
The clinical indicators recorded for participants with PD from
the participating neurologist included time since the onset of
PD symptoms, on time Hoehn and Yahr score, UPDRS
(subscales and overall scale), and current levodopa dosage
where available. Four of the participants were taking artane,
and three of these patients were also taking levodopa
medications. There was no significant difference between
the safety ratings of those participants with PD who were
taking artane and those not on this medication. The mean
age of the participants with PD and the controls did not differ
significantly (t44 = 0.67; p = 0.51). All testing (driving and
laboratory based) was undertaken when the participants
were optimally medicated. Table 1 summarises the group
characteristics.
Our study was conducted in accordance with the require-
ments of the Queensland University of Technology human
research ethics committee. All participants were given a full
explanation of the experimental procedures and written
informed consent was obtained, with the option to withdraw
from the study at any time.
To obtain an overall sense of the driving characteristics and
perceptions of the participants, a previously validated 57 item
questionnaire was administered.17 Questions related to
driving experience and habits, perceived difficulty (on a
scale of 1 (quite difficult) to 5 (quite easy)) for 24 specific
situations, and perceived difficulty (on the same 5 point
scale) for 12 specific tasks. The questionnaire also included
items relevant to PD, such as problems with moving the foot
from one pedal to another.
Driving performance
Driving performance was measured in an automatic, dual
brake vehicle under in traffic conditions using a previously
validated technique.18 19 An accredited professional driving
instructor, experienced in assessment, sat in the front
passenger seat and was responsible for maintaining vehicle
safety. A driver trained occupational therapist, experienced in
the assessment of driving and rehabilitation, sat in the rear
seat. Both assessed driving safety independently, using well
defined criteria. Neither was aware of the categorisation of
the participants.
All participants were directed to drive along the same
19.4 km open road route that contained a range of typical
driving situations. Seventy per cent of the driving was under
directed instruction and 30% was under self directed
navigation, where the participant had to find their own
way to a particular destination.
Occupational therapist assessment
The occupational therapist scored seven aspects of driving
performance at 147 locations along the route (general
observation, observation of blind spots, indication (signal-
ling), braking/acceleration, lane positioning, gap selection,
and approach). Failing any aspect of performance resulted in
failure of the whole task for a given location, giving an overall
score representing the percentage of locations where no
errors were made. The number of each error type was also
recorded. In addition, each of the 147 locations was allocated
to one of nine categories, including roundabouts, merging,
pulling in/pulling out, traffic light and non-traffic light
controlled intersections, reversing and parking, one way and
two way traffic, and lane changing. This allowed the
identification of situations where drivers had the most
difficulty.
The occupational therapist also gave an overall safety
rating from 1 to 10, according to current transport licensing
standards. A score between 1 and 3 indicated that the
instructor had to take action to avoid an incident, or that the
driver hit a significant object and should consider ceasing
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Figure 1 Correlation between the global driver safety ratings for all
participants assigned by the occupational therapist and the driving
instructor. The figure includes many overlying points.
10
8
6
4
2
0
18
Disease duration (years)
r = –0.60; r 2 = 0.36
D
riv
er
 s
af
et
y 
ra
tin
g
0 161412108642
Figure 2 The association between the time since diagnosis of
Parkinson’s disease (PD) and average driver safety rating for each of the
participants with PD. The figure includes some overlying points.
Table 1 Group mean (SD) of the characteristics of the
participant groups
Parkinson’s disease Control participants
Age (years) 63.7 (6.8) 65.2 (8.6)
UPDRS score 27.4 (11.3)
Hoehn and Yahr 2.3 (0.7)
Disease duration (years) 6.2 (4.6)
Mean levodopa dosage
(mg)
672.6 (512.5)
UPDRS, Unified Parkinson’s Disease Rating Scale.
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driving. A score of 4 or 5 indicated poor driving and
observation skills, whereas a score in the range of 6 to 8
indicated average driving skills, but with some bad habits.
Finally, a score of 9 or 10 reflected good to excellent driving
and observational skills.
Driving instructor assessment
The driving instructor provided an independent overall safety
rating using the same scoring criteria as the occupational
therapist. In addition, he recorded the number of critical and
non-critical driving errors made, and the number of
instructor interventions.
Participants rated the difficulty of the driving route and
conditions compared with their typical driving (on a scale of
1–5, where ‘‘1 = much easier’’ to ‘‘5 = much harder’’), and
their performance on the test compared with the typical
driver (on a scale of 1–5, where ‘‘1 = excellent’’ to
‘‘5 = poor’’).
Data analysis
The driving data were analysed using independent group
t tests to identify any group differences with directed or self
directed navigational instruction, and were broken down into
error types and locations. The familywise error rate was not
corrected for because, as this is one of the first descriptions
of driving error types and locations in PD, it was thought
important not to miss potential problem areas by using
unduly conservative methods. The safety ratings of the
occupational therapist and driving instructor were compared
to determine the level of inter-rater agreement, in addition to
the association with disease markers (time since diagnosis,
on time UPDRS and Hoehn and Yahr scale). For the driving
history questionnaire, those questions for which participants
used a scale from 1 to 5 were analysed parametrically using
independent t tests, whereas others were analysed non-
parametrically (Mann-Whitney U test). Modal categories are
reported as the measure of central tendency.
RESULTS
Driving history questionnaire
Drivers with PD and controls had similar driving experience
(modal category for both groups, ‘‘41–50 years’’; U = 238;
p = 0.56). Similarly, there were no significant group
differences for frequency of driving (modal category for both
groups, ‘‘every day’’; U = 238; p = 0.55), amount of time
driven each week (modal category for participants with PD,
‘‘3–4 hours/week’’ and for the controls, ‘‘. 7 hours/week’’;
U = 203.5; p = 0.18*), confidence felt when driving (modal
category for both groups, ‘‘confident’’; U = 236; p = 0.51),
amount of long distance (modal category for both groups,
‘‘1–2 times/year’’; U = 241.5; p = 0.19) or highway driving
(modal category for both groups, ‘‘a few times each month’’;
U = 215; p = 0.37), or driving in unfamiliar areas (modal
category for both groups, ‘‘confident’’; U = 231; p = 0.10).
There were also no significant differences between groups
for self reported crashes (modal category for both groups, ‘‘no
crash within past 10 years’’; U = 259; p = 0.92), with
seven of the 21 controls and eight of the 25 participants with
PD reporting a crash within the previous 10 years.
However, the drivers with PD reported driving significantly
fewer kilometres than controls (modal category, ‘‘60–90’’
compared with ‘‘. 90 km/week’’; U =144.5; p = 0.004),
and were significantly less confident driving alone (modal
category, ‘‘confident’’ compared with ‘‘very confident’’;
U = 167.5; p = 0.015). Only three of the 36 driving
conditions or tasks were rated as significantly more difficult
by the drivers with PD (on a scale of 1 to 5): reading road
Table 2 Overall driving score and types of driving errors made by the two groups as assessed by the occupational therapist
Driving scores
Participant groups Statistics
Controls Parkinson’s t Value p Value
Overall score % 83.95 (1.61) 77.18 (2.15) 2.43 0.02
Critical errors 0.38 (0.17) 1.12 (0.36) 21.75 0.09
Observation errors 3.14 (0.63) 5.04 (0.93) 21.62 0.11
Blind spot errors 5.19 (0.66) 7.52 (0.74) 22.30 0.03
Indicator errors 6.09 (0.58) 6.80 (0.77) 20.71 0.48
Brake/accelerator errors 8.19 (1.26) 9.80 (1.76) 20.72 0.48
Lane keeping errors 4.62 (1.00) 10.20 (1.62) 22.80 0.01
Gap selection errors 3.62 (0.60) 4.40 (0.63) 20.89 0.38
Approach errors 8.28 (1.24) 10.36 (1.57) 21.00 0.32
Directed errors 27.14 (3.64) 38.60 (4.40) 21.96 0.06
Self directed errors 12.00 (1.89) 15.52 (2.26) 21.17 0.25
Values are mean (SD).
*This apparent difference was caused by a non-normal distribution: a
subgroup of the controls drove longer distances. However, the mean
values were in the same category of 3–4 hours/week.
Table 3 Locations at which driving errors were made by the two groups as assessed by the occupational therapist
Locations
Participant groups Statistics
Controls Parkinson’s t Value p Value
Roundabouts 4.71 (0.68) 4.56 (0.75) 0.15 0.88
Merging 1.33 (0.26) 2.16 (0.37) 21.75 0.09
Pulling in/pulling out 4.19 (0.36) 3.92 (0.29) 0.59 0.56
Traffic light controlled intersection 6.23 (1.00) 10.36 (1.73) 21.95 0.05
Non-traffic light controlled intersections, stop and give way 4.19 (0.86) 6.64 (1.17) 21.64 0.11
Reversing, car parking 2.28 (0.57) 3.84 (0.54) 21.98 0.05
One way (no oncoming traffic) 3.33 (0.67) 4.92 (0.70) 21.62 0.11
Two way (oncoming traffic) 6.09 (1.38) 7.72 (1.11) 20.92 0.36
Lane changing 5.85 (1.02) 8.84 (1.11) 21.94 0.05
Values are mean (SD).
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signs in daylight (t44 = 2.41; p = 0.02), moving their foot
from one pedal to another (t44 = 2.73; p = 0.009), and
steering (t44 = 2.80; p = 0.008). However, in all cases,
groups differed by no more than one category—for example,
‘‘fairly easy’’ versus ‘‘quite easy’’.
Driver safety ratings: occupational therapist and
driving instructor assessments
The safety ratings recorded for each of the participants with
PD and the controls by the occupational therapist and driving
instructor were highly correlated (fig 1), so we used the mean
of the two raters’ scores. These show that the drivers with PD
were rated as significantly less safe on a scale of 1–10 (mean,
4.80; SD, 1.91) than the controls (mean, 6.56; SD, 1.72)
(t44 = 3.26; p = 0.002).
When the safety ratings were considered individually, five
of the 25 drivers with PD scored between 1 and 3, a score
defined as a driver for whom the instructor had to take action
to avoid an incident, or the driver hit a significant object and
should consider ceasing driving. Furthermore, 14 of the 25
drivers with PD scored 5 or less, indicating that they would
have failed the Queensland driving test, as compared with
five of the 21 controls.
Examination of the safety ratings of the drivers with PD
and clinical disease indicators showed that time since
diagnosis was significantly correlated with driver safety
ratings (r = 20.60; p = 0.001)—the longer the time since
diagnosis, the lower the patient’s rating (fig 2). This
association remained significant even when age was par-
tialled out (r1,2.3 = 20.47; p = 0.02). However, driver
safety ratings were not significantly correlated with either
on time UPDRS (r = 20.24; p = 0.25), the Hoehn and
Yahr scale (r = 20.06; p = 0.79), or levodopa dosage
(r = 20.36; p = 0.11).
Self reported driving and safety rating
Those in the PD group rated their driving skills more poorly
compared with an average driver (M = 2.98) than did the
controls (M = 2.57), and these differences reached signifi-
cance (t44 = 22.71; p = 0.009). However, those with PD
did not rate the driving route and conditions as harder
than the control participants (patients with PD, M = 3.4;
controls, M = 3.19; t44 = 21.20; p = 0.24). Importantly,
there was no relation between an individual’s self rating of
driving performance and their safety rating (r = 20.22;
p = 0.14), and this was the case for both the drivers with PD
and the controls.
Types and locations of driving errors
The overall safety scores recorded by the occupational
therapist were significantly worse for the PD group than for
controls, and both groups made proportionally more errors
under self directed than directed navigation, but these
differences did not reach significance (table 2). The drivers
with PD made significantly more errors involving lane
keeping and observation or monitoring of the blind spot
than did the controls.
Table 3 shows the breakdown of errors by location type.
The drivers with PD made significantly more errors at traffic
light controlled intersections and at locations involving
reversing, car parking, and lane changing.
Driving instructor
Apart from rating the drivers with PD as less safe than
controls, the driving instructor also had to intervene more
often to avoid an incident than for the controls (table 4). The
drivers with PD also made significantly more critical errors
than did the controls.
DISCUSSION
The drivers with PD were rated as significantly less safe than
control participants by both the occupational therapist and
the driving instructor on a standardised open road course.
This finding is in general agreement with that of Heikkila¨
et al,14 who reported that 35% of drivers with PD were rated as
unsafe to drive compared with control subjects. Radford et al
reported similar findings but did not include a control
group.15
The drivers with PD made significantly more errors than
controls in lane keeping and lane changing, reversing,
parking, monitoring of their blind spot, and negotiating
traffic light controlled intersections. The driving instructor
also had to intervene significantly more often for drivers with
PD. These errors probably stem from some combination of
decreased motor control skills, impaired visuo-spatial proces-
sing, sequence control, and planning in the drivers with PD.
However, the current data do not allow this impaired
performance to be attributed to any specific process. These
practical skill findings agree with the questionnaire data from
the drivers with PD, which showed that these patients had
significantly more problems with steering and moving their
feet between pedals. They also confirm the findings of
Radford et al,15 that patients with PD display a lack of
observation at junctions, poor road positioning, and poor
driving at roundabouts. However, their results must be
considered with caution because of their limited sample size.
Importantly, the global driver safety ratings could not be
predicted by the on time UPDRS or the Hoehn and Yahr scale,
but had a stronger association with disease duration.
Although previous studies have reported that various indices
of driving performance have been predicted by the
Webster’s,8 Hoehn and Yahr,12 and UPDRS scales,10 there
has been considerable disagreement in the literature.9 Some
researchers have used driving simulators, which have been
shown to be poor predictors of true performance,11 or report
on small and potentially unrepresentative samples. Indeed,
Heikkila¨ et al found that speed of visual processing,
medication use, and age were better predictors of open road
driving performance than were clinical disease indicators,
although, as in our study, the association between levodopa
dosage and driving safety alone was not strong.14 These
findings confirm the fact that currently used clinical disease
markers do not adequately capture those aspects of PD that
are linked with unsafe driving performance.
Table 4 Driving performance scores recorded by the driving instructor
Driving scores
Participant groups Statistics
Controls Parkinson’s t Value p Value
Instructor interventions 0.14 (0.08) 0.64 (0.18) 22.36 0.02
Critical errors 0.76 (0.30) 2.24 (0.58) 22.14 0.04
Non-critical errors 3.09 (0.32) 3.44 (0.37) 20.69 0.49
Values are mean (SD).
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The questionnaire findings suggest that the drivers with
PD in this volunteer sample limit their own driving habits
only to a minor degree, driving as often as controls, but
covering fewer kilometres and driving alone less often. These
findings are not surprising given that the individuals with PD
and controls reported similar driving confidence levels.
Importantly, an individual’s self rated performance was a
poor predictor of their driving safety, and this was true for all
participants. This finding confirms the conclusion of Heikkila¨
et al,14 and suggests that it is unrealistic to expect individuals,
with or without PD, to determine their own safety levels.
Instead, it emphasises the importance of identifying objec-
tive, evidence based predictors of driving safety, which can be
used to inform the treating practitioner and the licensing
authority, and to educate and assist drivers in the use of
compensatory behaviours. This was the objective of a larger
study conducted by our research group, which includes the
evaluation of visual, cognitive, and motor tests as predictors
of safe driving performance.
It is also important to note that the drivers with PD in our
study had chosen to continue driving, had retained their
licence, and had volunteered to participate in our study—and
are therefore likely to drive better than average, given that
many patients with PD choose to stop driving.20 The current
results probably overestimate the driving performance of the
wider PD population, and may under-represent the true
driving performance decrement that accompanies the dis-
ease. In addition, these driving performance scores were
obtained during optimal on time medication and do not
address the impact of symptom fluctuations in PD.
CLINICAL IMPLICATIONS
Together, these findings have important implications that
should be considered by health professionals dealing with
patients with PD.
N At diagnosis, drivers with PD need advice regarding the
potential impact of PD on driving, given that our study
provides clear evidence that drivers with PD are signifi-
cantly less safe than control drivers.
N Drivers with PD probably have limited awareness of their
deteriorating driving performance and need regular
monitoring. It is unrealistic to expect individuals, particu-
larly those with PD, to be aware that their driving is
becoming unsafe and to adopt compensatory behaviours.
This clearly indicates the importance of identifying
predictors of unsafe performance and making them
available for use by a patient’s neurologist and to assist
in the licensing process.
N Appropriately timed referral to occupational therapy
driving assessment services to determine fitness to
continue driving or the need for driving rehabilitation
may enable drivers with PD to make more realistic plans
for the future, whether to limit their driving, or stop
altogether.
N Drivers with PD may benefit from targeted driver
retraining. Our study clearly indicates that there are
specific areas of difficulty that are more common in
individuals with PD. It may be possible to use targeted
interventions and retraining to prolong the length of time
that patients with PD might drive safely and hence
maintain their independence.
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Possible transcallosal seizure
induction by paired pulse
transcranial magnetic stimulation
in a patient with frontal lobe
epilepsy
Seizure induction by high frequency trans-
cranial magnetic stimulation (TMS) has been
reported in normal subjects and by single
pulse TMS close to the epileptic focus in
patients with epilepsy.1
Case report
We report an 18 year old patient with right
frontal lobe epilepsy due to paramedian focal
cortical dysplasia (FCD). The patient’s usual
seizure semiology consisted of a somato-
sensory aura of the left hand followed by
a tonic seizure of the left arm which evolved
to a bilateral asymmetrical tonic seizure
without loss of consciousness. In the two
years preceding the study (see below) he
had rare night-time seizures only. His anti-
epileptic medication consisted of levetirace-
tam 500 mg, phenobarbital 25 mg, and
carbamazepine 1600 mg daily.
During presurgical videoelectroencephalo-
gram (video-EEG) monitoring, interictal EEG
showed right frontotemporal spikes. Ictal
EEG revealed seizure patterns with a right
frontal onset. Magnetic resonance imaging
(MRI) showed FCD in the right superior
frontal gyrus extending into the right pre-
central gyrus (fig 1A). Neurological examina-
tion was normal.
Transcranial magnetic stimulation
The patient participated in a TMS study using
a protocol described previously2 to evaluate
intracortical excitability of both motor cor-
tices (M1). The study was approved by the
local ethics committee, and the patient gave
written informed consent.
We used a focal 70 mm figure of eight coil
connected to two magnetic stimulators via a
BiStim module (Magstim Company, Dyfed,
UK). Surface electromyography (EMG) was
recorded from the contralateral abductor
digiti minimi muscle (ADM) of the hand.
TMS commenced over the left M1 contra-
lateral to the epileptic focus with the coil
placed over the M1 hand area. First, motor
thresholds (RMT, AMT) and cortical induced
silent period at an intensity of 110% RMT
were evaluated. Next, paired pulse TMS
(conditioning stimulus set at 38% of max-
imum stimulator output, second stimulus
60% of stimulator output) was started on
the left M1 with a train of paired pulses with
ISI 2, 3, 10, and 15 ms in a random order.
After 65 stimuli, the patient noticed that
his habitual somatosensory aura of the left
hand followed by myoclonic jerks of the left
forearm (mainly biceps brachii muscle and
forearm flexor muscles) was triggered by
each stimulus, contralateral to the epilepto-
genic zone but ipsilateral to the cortical
stimulation. The jerks were triggered by both
single and paired stimuli at all ISI and rapidly
involved both arms. These motor phenomena
were different from the typical seizure
semiology. EMG recordings of the ADM
showed movement artefacts 63–75 ms after
the MEP (fig 1B). The TMS was immediately
interrupted, which aborted the myoclonus at
once.
The TMS data of the left hemisphere
showed increased motor thresholds, pro-
longed cortical induced silent period, mark-
edly decreased intracortical inhibition, and
increased facilitation compared with 20 con-
trols2 (percentiles of the patient’s measures
within the control group: .99% for ISI 2 and
CSP, .95% for motor thresholds and ISI 15,
.90% for ISI 10, and .85% for ISI 3).
After the TMS experiment, the patient was
again free of daytime seizures until the last
follow up visit six months later.
Transcallosal seizure induction by
paired pulse TMS
In patients with epilepsy, all reported cases of
seizure induction by TMS have occurred
during ipsilateral stimulation and near to
the epileptic focus. Therefore, it has been
assumed that direct stimulation of the
epileptogenic tissue was required to trigger
a seizure.1 We used a focal coil placed over the
left M1 hand area more than 5 cm away from
the midline. Thus, it is unlikely that the right
epileptogenic zone or mesial frontal cortex of
the present patient was stimulated directly,
and we assume that an indirect transcallosal
activation of the epileptogenic zone provoked
the aura. The latency of 65–75 ms of the
myoclonic jerks after the MEP may reflect
polysynaptic pathways in addition to a direct
transcallosal connection of both M1. It is still
not clear whether involvement of additional
cortical areas such as the ipsilesional and
contralesional sensory cortices or basal gang-
lia contributed to the seizure provocation.
Despite the patient’s statement that the jerks
were not volitional, this cannot be completely
ruled out. The preceding somatosensory aura,
however, represented his typical seizure
semiology. We hypothesise that transcallosal
activation of the epileptic focus was pro-
moted by the increased excitability of M1,
which was due to the underlying FCD. This,
in turn, led to the aura and peri-ictal changes
in M1 excitability facilitating TMS driven
myoclonic jerking. It has been previously
reported that FCD is intrinsically epilepto-
genic and promotes reflex seizures.3
There is a possibility that ipsilateral path-
ways of movement activation could underlie
our observations. In a child with extensive
cortical dysplasia, TMS of the unaffected
hemisphere evoked MEPs in both ADM
muscles implying bilateral corticospinal con-
nections from one cortex.4 Histological stu-
dies on severe brain damage in early
development have revealed collateral sprout-
ing into denervated areas of cortex or spinal
cord.4 Ipsilateral activation under maximum
muscle contraction has been observed in
healthy volunteers and in patients with acute
stroke.5 Our patient, however, presumably
had congenital but circumscribed FCD, no
motor deficits, and was investigated at rest.
This and the fact that his habitual somato-
sensory aura occurred before the myoclonic
jerks strongly argue against the activation of
ipsilateral corticospinal tracts. Activation of a
silent mirror focus in the left hemisphere
with subsequent spread to the right is also
unlikely because exclusively right sided ictal
and interictal epileptiform discharges were
recorded during the video-EEG monitoring.
Changes in motor cortex excitability
Our patient’s higher motor thresholds com-
pared with controls are very likely due to
his ion channel blocking anticonvulsant
medication.6
  
Figure 1 (A) Axial T2-weighted magnetic resonance imaging (MRI) scan (fluid attenuated
inversion recovery (FLAIR)) of the patient’s brain. T2 prolongation and blurring of grey-white
junction represents focal cortical dysplasia of 161 cm (see circle) located in the right superior
frontal sulcus (extending to the right motor cortex, seen in further MRI slices). (B) Examples of motor
evoked potentials (MEPs) from the right abductor digiti minimi muscle (ADM) during transcranial
magnetic stimulation of the left hemisphere at different interstimulus intervals (ISI) and after
unconditioned test stimulus. The patient showed stimulus triggered myoclonic jerks of both hands
and forearms leading to movement artefacts in the ADM recordings.
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The loss of intracortical inhibition and
increased intracortical facilitation in the left
hemisphere contralateral to the epileptogenic
zone may reflect synaptic reorganisation of
the ipsilesional and contralesional motor
cortices. These distant functional cortical
changes associated with malformations
of cortical development have also been
described previously.7 The prolongation of
the cortical induced silent period seen in the
present patient may be independent of the
phenobarbital intake6 and confirms similar
findings from previous studies as a remote
effect of FCD on the motor cortex in
untreated patients with cortical dysgenesis.7
Conclusion
Unilateral epileptogenic FCD involving M1
can induce complex bilateral alteration of
motor cortex excitability resulting in a net
increase of excitability. In such cases, trans-
callosal seizure induction appears to be
possible with paired pulse TMS using a focal
coil away from the epileptic focus.
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Hashimoto’s encephalopathy:
steroid resistance and response
to intravenous immunoglobulins
Hashimoto’s encephalopathy is a steroid
responsive disorder characterised by high
titres of anti-thyroid antibodies and mani-
festing as sub-acute onset of confusion,
episodes of myoclonus, seizures, and stroke-
like episodes. Although excellent response to
steroids is characteristic, other treatments
such as plasmapheresis or administration of
azathioprine or cyclophosphamide have been
occasionally tried. We report a case of initially
steroid responsive Hashimoto’s encephalo-
pathy which became steroid resistant and
then responded well to intravenous immuno-
globulins.
Case report
A 29 year old woman was admitted in 1987
with an episode of headache, confusion,
agitation, and hallucination. She had a mild
fever and was thought to have neck stiffness.
A CT scan was normal as were the inflam-
matory markers. CSF examination showed
9240 red cells and 33 white cells (45%
polymorphs and 55% lymphocytes). CSF
protein, glucose, and microbiology were
normal. A presumed diagnosis of meningo-
encephalitis was made and the patient was
treated with acyclovir and antibiotics. The
patient made a good recovery but was re-
admitted a week later with agitation and
confusion with pain and weakness down the
left side. No focal neurology was found on
examination and the patient was thought to
be suffering from an anxiety state.
During the next 14 years, the patient was
admitted on several occasions with episodes
of confusion and agitation: investigations
including lumbar puncture, CT scans, EEG,
thyroid function, porphyria screens, autoanti-
body screens (including antinuclear anti-
bodies, ANCA, and those against extractable
nuclear antigens), and metabolic and septic
screens were found to be normal. She had
been admitted to the psychiatry unit and was
thought to be suffering from acute mania or a
dissociative state, precipitated by stress and
sleep deprivation. In 2001, she was referred to
the neurology clinic for similar episodes,
which were increasing in frequency.
On first review in the neurology clinic,
clinical examination was unremarkable
except for bilaterally symmetrical and brisk
reflexes. MRI scan of the brain and EEG were
repeated and found to be normal. Thyroid
peroxidase antibody was raised at 250 IU/ml
(normal range 0–60). Thyroid function tests
were normal.
She remained well until April 2003 when
a further episode of drowsiness and confu-
sion occurred (thyroid peroxidase antibody
266 IU/ml). This responded remarkably and
within 24 h to a course of dexamethasone
given intravenously at a dose of 16 mg daily
for 5 days. An EEG repeated during the
episode showed diffuse slowing but no
epileptiform abnormalities.
The patient was re-admitted in May 2004
with another episode of confusion and
agitation. Interestingly, this episode occurred
after a 5 day course of oral prednisolone
60 mg/day for a chest infection. Apart from
the acute confusional state there was no focal
neurology. Repeat CT scan and CSF examina-
tion including oligoclonal bands were within
normal limits. Repeat thyroid peroxidase
antibody was elevated at 272 IU/ml (normal
range 0–60). Voltage gated potassium chan-
nel antibodies were negative. Other investi-
gations including thyroid function remained
normal. EEG showed diffuse bilateral slow
wave activity. A 7 day course of intravenous
dexamethasone 16 mg/day was initiated.
The confusion and agitation worsened and
later she became very drowsy. Intravenous
immunoglobulin (400 mg/kg daily) was given
causing a dramatic improvement within 12 h.
Unfortunately, on the same day, the patient
developed an increase in alanine transaminase
and C-reactive protein levels. A possible
reaction to intravenous immunoglobulin was
considered and the infusionwas discontinued.
Later, the increased levels were confirmed
to be secondary to septicaemia from a
Staphylococcus aureus infected cannula site.
The inflammatory markers normalised after
a course of antibiotics. During this time the
patient remained drowsy, confused, and occa-
sionally agitated. A 5 day course of intrave-
nous immunoglobulin was reinstated. Again,
there was a dramatic improvement within
24 h and she was discharged home at the end
of the course having completely recovered.
Discussion
Hashimoto’s encephalopathy (HE) is a ster-
oid responsive disorder characterised by high
titres of anti-thyroid antibodies. The original
description of this condition was in an
established case of Hashimoto’s thyroiditis
where the patient developed focal neurologi-
cal deficits and coma.1 Clinical presentation
includes episodic confusion, myoclonus, sei-
zures, and stroke-like episodes.2 Females are
more affected than males (3.6:1), with a
mean age of onset of 41 years. The hallmark
of HE is its response to steroids, most cases
improving within a few hours to days.3 The
titres of anti-thyroid antibodies maybe inde-
pendent of the severity of the clinical
presentation.4 Fewer than 100 cases of HE
have been reported in the literature. Goitre
and hypothyroidism can be associated with
the disorder, but the majority of patients are
euthyroid. Although steroid responsiveness is
the rule, additional immunosuppressive ther-
apy in the form of azathioprine and cyclo-
phosphamide has been tried in a minority of
patients.2 3 One case report of HE responding
to plasmapheresis is documented.5 There was
no benefit in the two documented cases
where intravenous immunoglobulin was
administered.5 6
Several pathophysiological hypotheses have
been suggested for HE. The initial report of
HE suggested a vascular aetiology followed
by localised cerebral oedema as a possible
mechanism.1 Some authors suggest that the
CSF thyroid autoantibodies may react with a
putative CNS antigen and form immune
complexes.2 4 The immunopathological basis
of this syndrome has been compared to a
relapsing form of acute disseminated
encephalomyelitis.7 Although reversible MRI
findings have been described in HE,8 neuro-
imaging (except for isolated patchy uptake by
isotope scans) is usually normal in most
cases.3 Cerebral angiography has been found
to be normal in several cases of HE, unlike in
many other cerebral vasculitides.1–3 5
Thyroid autoantibodies can co-exist with
several other forms of autoimmune encephalo-
menigitis, but the normal MRI scan, the
initial dramatic response to steroids, and
negative autoantibodies for most other com-
mon vasculitides, tends to favour the diag-
nosis of HE in our case. Steroid responsive
encephalopathy associated with Hashimoto’s
thyroiditis is an alternately proposed name
for this condition,9 but the vast majority of
cases have normal thyroid function, leaving
‘‘Hashimoto’s encephalopathy’’ a universally
accepted term. A recent literature review of
85 patients with encephalopathy and anti-
thyroid antibodies suggests that the combi-
nation of encephalopathy, high serum
anti-thyroid antibody concentrations, and
Competing interests: none declared
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responsiveness to glucocorticoid therapy seems
unlikely to be due to chance.10
The initial meningo-encephalitic type pre-
sentation of our patient in 1987 was probably
the first manifestation of HE in view of
clinical findings and laboratory data (Mild
CSF pleocytosis is not unusual in HE.3) There
was a delay of 14 years before the diagnosis
was first established, in spite of several
hospital admissions. The initial relapses after
diagnosis responded well to steroids, con-
firming the diagnosis of HE. Whether
the current episode was precipitated by the
sudden withdrawal of oral steroids or the
chest infection itself, for which they were
prescribed, is unclear.
Our patient illustrates the possibility of
steroid resistance in an established case of HE
and the need to consider further immuno-
modulatory therapy. Intravenous immuno-
globulins are a safe, convenient, and effective
treatment in such circumstances.
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Spontaneous lobar haemorrhage
in CADASIL
CADASIL is an autosomal dominant form of
arteriopathy, primarily affecting cerebral ves-
sels, and predominantly caused by point
mutations in the Notch3 gene on the short
arm of chromosome 19.1 Affected individuals
develop subcortical strokes and cognitive
deficits in their 50s and 60s.2 Brain magnetic
resonance imaging (MRI) shows large areas
of leukoencephalopathy and multiple sub-
cortical lacunar infarcts. Small arteries and
capillaries are characterised histologically by
a non-atherosclerotic, non-amyloid angio-
pathy with accumulation of granular osmio-
philic material (GOM) within the smooth
muscle cell basement membranes and extra-
cellular matrix.3 While CADASIL is consid-
ered a primarily ischaemic form of vascular
dementia, microhaemorrhages have recently
been reported in 31% of symptomatic Notch3
mutation carriers, suggesting that structural
fragility of the arterial walls may lead to
leaking of haem products.4 Lobar haemor-
rhage in the absence of other risk factors for
haemorrhage has previously been reported in
one patient with CADASIL.5 Here we report a
second case.
Case report
A 56 year old man who had been diagnosed
with multiple sclerosis six years earlier was
admitted to the hospital with an acute
change in mental state. He had collapsed at
home and was unresponsive when rescue
arrived. In the emergency room he had a
depressed level of consciousness and diffi-
culty following commands, with paucity of
speech, dysarthria, and hypophonia. There
was no evidence of head trauma. His blood
pressure was 100/63 mm Hg and his tem-
perature was 36.1 C˚.
Past medical history included chronic
obstructive pulmonary disease, prostate
resection for prostate cancer, and a history
of nicotine and alcohol dependence. He had
no history of hypertension, diabetes mellitus,
or coagulopathy. His drug treatment included
ipratropium, ranitidine, methyprednisolone,
and albuterol. His mother, now deceased, had
been diagnosed as having multiple sclerosis
and had migraines with auras, stroke-like
symptoms, and dementia. He had eight
siblings, three with headaches and one with
recent transient ischaemic events.
Computed tomography (CT) of the head in
the emergency department showed an area of
high attenuation in the right frontal lobe
consistent with an acute intraparenchymal
haemorrhage (fig 1A). There was no evidence
of trauma on head CT. Gradient echo MRI
sequences of the brain done on hospital day 2
showed a 262.5 cm area of haemorrhage in
Competing interests: none declared
Figure 1 (A) Non-contrast computed tomography of the head done in the emergency room
showing an area of high attenuation in the right frontal lobe consistent with acute haemorrhage.
The other panels show non-contrast magnetic resonance imaging done on hospital day 2:
(B) Gradient echo sequence demonstrating a 262.5 cm area of haemorrhage in right frontal lobe,
a microhaemorrhage in the right parietal region, and extensive white matter disease. (C, D) The
area of haemorrhage is hypointense on T2 and isointense on T1 weighted imaging, consistent with
an acute haemorrhage.
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the superior-anterior aspect of the right
frontal lobe white matter as well as a
microhaemorrhage in the right parietal
region (fig 1B). The area of haemorrhage
was hypointense on T2 (fig 1C) and iso-
intense on T1 weighted sequences (fig 1D),
consistent with acute haemorrhage. There
was no MRI evidence of a cavernous haem-
angioma, arteriovenous malformation, or
tumour. Magnetic resonance angiography
was not done.
A brain biopsy of the right frontal lobe
done on the seventh hospital day showed
degeneration of small and medium sized
arteries. Vessel walls were thick and hyali-
nised in the grey matter, white matter, and
meninges. PAS staining was positive and the
muscular coat of the large vessels revealed
degenerative changes. Electron microscopy
showed the granular osmiophilic material
characteristic of CADASIL. Notch3 gene test-
ing revealed a R133C mutation in exon 4,
consistent with the diagnosis of CADASIL.
The patient remained normotensive through-
out his hospital stay. On the fifth hospital day
he developed aspiration pneumonia requiring
mechanical ventilation. He died eight days
later as a result of this pneumonia.
Comment
This is the second report of spontaneous
cerebral haemorrhage in a patient with
CADASIL. In 1977, Sourander and Walinder
reported a 29 year old man with hereditary
multi-infarct dementia on anticoagulants,
with a large haemorrhage in the right hemi-
sphere.5 This family was thought to be one of
the first with CADASIL; however, recent
testing for Notch3 mutations in the family
has not confirmed that diagnosis.6 In 1992,
Baudrimont et al reported a case of massive
left cerebral haematoma involving the cau-
date nucleus, internal capsule, and thalamus
in a 40 year old normotensive woman who
was a member of a large CADASIL family.
She had no known history of other risk
factors for haemorrhage.7
The index patient in this report had no
evidence of coagulopathy and no history of
previous hypertension, cerebral haemor-
rhage, or anticoagulant therapy. The patient
could have experienced a haemorrhagic con-
tusion related to a closed head injury during
his unwitnessed fall before admission, but
there was no evidence of trauma on physical
examination or on head CT. On MRI there
was no evidence of a cavernous haem-
angioma, arteriovenous malformation, or
neoplasm. Necropsy was not carried out.
Ultrastructural analysis of small arteries in
human postmortem brain and skin in
patients with CADASIL shows breakdown of
the arterial wall cytoarchitecture, which may
help explain the propensity for microhaemor-
rhages.8 The first notch3 transgenic mouse
shows early widening of the subendothelial
and intra-smooth-muscle spaces in the vas-
cular smooth muscle cells, denoting weaken-
ing of the arterial wall and increasing
susceptibility to micro- and macrohaemor-
rhages.9
This case report supports the growing
evidence for both ischaemia and haemorrhage
in a variety of small artery diseases includ-
ing amyloid angiopathy and CADASIL.10 11
Clinicians may need to consider the possibility
of haemorrhage when evaluating new events
and deciding on treatment for stroke preven-
tion in patients with CADASIL.
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Urinary retention caused by a
small cortical infarction
The cortical representation of micturition is
speculated to reside in the medial frontal
lobes.1 2 Lesion pathology, however, varies
from acute stroke to a neoplasm, and there is
not necessarily a small, distinct lesion.2 We
report a case of urinary retention in which
the main presenting symptom is thought
to have been caused by a small cortical
infarction.
Case report
One morning, a 66 year old, right handed
man had difficulty urinating. He had no
history of voiding difficulty, diabetes melli-
tus, injury to the lower urinary tract, or
neurological disease. Digital rectal examina-
tion and ultrasonography of the prostate
detected no enlargement. Urinalysis showed
no haematuria or pyuria. He was not taking
any medications that cause voiding dysfunc-
tion. There was no urinary incontinence, but
he had difficulty in voiding even though he
felt the bladder was full. At that time, he also
had difficulty in lifting his left arm and leg
and so was brought to our hospital.
Neurological examination in the emergency
room found no weakness, and he was sent
home. Later, he experienced urinary reten-
tion and visited the emergency room again.
His post void residual urine volume was
350 ml, and an urinary catheter was inserted.
At that time the patient was alert, and his
cranial nerves were intact. Limb muscle
strength was normal. Sensory examination
was unremarkable. Tendon reflexes were
normal in all four limbs. Tandem gait and
standing on one foot were difficult. He had
normal bladder sensation but difficulty in
urinating. Drip infusion pyelography revealed
no abnormality in the upper urinary tract or
the form of the bladder. Filling cystometry
showed stable detrusor with normal bladder
sensation, whereas acontractile detrusor was
noted in the voiding phase. He could void
only with strain, having a peak flow rate of
5.0 ml/s and a voided volume of 135 ml.
Diffusion weighted MRI, performed on the
day of onset, showed a small, distinct, high
intensity signal, and T1 weighted imaging
showed a low signal in the right caudal part
of the anterior cingulate gyrus, indicative of
an infarct in the acute stage (fig 1A and C).
No definitive infarct was observed elsewhere.
MR angiography showed no occlusion or
stenosis of the intracranial vessels. An elec-
trocardiogram was normal. Transthoracic
echocardiograms showed no abnormal find-
ings. The urinary catheter was withdrawn
3 days after admission, and he had no
subsequent difficulty with urination. His gait
returned to normal about the same time.
Discussion
In the acute stage of a cerebral vascular
accident, the presenting symptom often is
urinary retention due to detrusor areflexia,3
but patients who have this problem usually
have a major stroke with severe neurological
deficits.
To the best of our knowledge, this is the
first report in the English literature of urinary
retention, although temporary, caused by a
small cortical infarct as shown by diffusion
weighted MRI.
Various cortical areas are activated during
voiding because a network of brain regions is
necessary for voiding modulation.4 The loca-
tions of the primary cerebrum cortical areas
for voiding and storage are speculated to be
separate, the former being at the para-central
lobule.2 A PET study found normal micturi-
tion to be associated with activation of the
middle frontal gyrus, superior frontal gyrus,
superior precentral gyrus, thalamus, and the
caudal part of the anterior cingulate gyrus in
the left hemisphere.5 Another recent PET
study showed that increased brain activity
related to increasing bladder volume was
located in the bilaterally mid-cingulate cor-
tex, while that related to decreased urge to
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void was bilaterally in a different portion of
the mid-cingulate gyrus.4
Although the infarct in our patient was
located in the caudal part of the anterior
cingulate gyrus, it was on the right side,
nearby the region activated in the PET study.4
SPECT showed increased blood flow in the
right medial frontal area, indicative that
urinary retention was due to ‘‘decreased urge
to void’’, and decreased flow in the right
medial parietal lobe, which might explain the
gait disturbance, in light of the essentially
normal sensory examination. Unfortunately,
a PET scan was not available in our hospital
(Kameda Medical Center). Because there has
been no report of an isolated lesion of the
cingulate gyrus causing hemiparesis, these
brain imaging studies indicate that the left
hemiparesis, which disappeared within a half
day of onset, could have been due to a
transient ischaemic attack.
Urinary symptoms disappeared 3 days
after admission, probably because the cortical
neuron network compensated by providing a
functional alternative to the lesion damaged
by the infarct. This is similar to the condition
of urinary incontinence after cerebral infarc-
tion, as is well documented. The laterality of
the lesion in this patient differs from that in a
previous PET study4 which showed bilateral
activation in the cingulate gyrus. Because this
report cites only a single case, its applicability
is limited. Additional lesion studies of
patients with micturition disturbance due to
small cortical infarcts should help to identify
the anatomical cerebral structures involved in
voiding.
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Figure 1 Diffusion weighted MRI. (A) The axial section shows a small high signal in the right caudal part of the anterior cingulate gyrus. (B) The closed
ellipse denotes the lesion in the cortical map (map modified from Brodmann, 1909). (C) In the T1 weighted MRI procedure, the coronal section shows a
low intensity signal in the right caudal part of anterior cingulate gyrus (arrow). (Imaging condition: a negative tilt of 220˚ to the orbitomeatal line.)
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BOOK REVIEW
particular disorder may not be found in the
index chapter on that disorder, but in this
later section. For example, the only discus-
sion of suicide following head injury in the
chapter on head injury is a single misleading
sentence indicating that suicide accounts for
10% of head injury deaths. Yet, easily missed,
300 pages later, in the chapter on the
neurological origins of suicide, is a more
complete account of the relationship.
Overall, however, this book is a significant
achievement. A large amount of material has
been made readily accessible. There are no
lacunae and the length of discussion of each
disorder is proportionate to its importance.
The book is to be trusted and recommended.
One interesting innovation is a list of support
groups and useful websites in the appendix.
Neurologists and psychiatrists and their
trainees have good reason to buy this book.
S Fleminger
Neuropsychiatry and behavioural
neurology explained
Edited by A J Mitchell. Published by Saunders,
London, 2004, £69.00 (hardback), pp 500.
ISBN 0-7020-2688-3
This is an ambitious project for a single
author; the whole of neuropsychiatry
explained using an up to date, evidence based
review of the literature, and in a format that
is designed to be attractive to read. There are
numerous figures, boxes, lists with bullet
points, and ‘‘clinical pointers’’ to break up the
text.
Although aimed particularly at liaison and
old age psychiatrists, this book will have wide
appeal and be of interest to neurologists.
They will be able to quickly access clinically
relevant discussion of the neuropsychiatric
sequelae of common neurological disorders.
The core sections of the book, on dementia
and delirium, neuropsychiatric treatments,
and the psychiatric complications of neuro-
logical diseases, are excellent. The discussion
is practical and to the point. The reader is not
stifled with references strewn in the text.
They must therefore have confidence in the
assertions of the author; I am confident that
we are being offered accurate information.
But at times the style feels a little pedantic;
for example, those of us who dared to believe
that alcohol might cause depression are put
firmly in our place. Another quibble I have is
the value of some of the lists/classifications
which were of uncertain provenance. We are,
for example, given lists suggesting difference
aetiologies for chorea versus athetosis, but
some would be sceptical of the value in
splitting choreoathetosis. Many classifica-
tions are based on neuroanatomical models
of neuropsychiatry that need to be treated
with caution.
The book strays into biological psychiatry,
and a later section is devoted to under-
standing how neurological disorders result
in neuropsychiatric symptoms, but this does
cause a problem because some of the discus-
sion of the neuropsychiatric sequelae of a
CORRECTIONS
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Wood J M, Worringham C, Kerr G, et al.
Quantitative assessment of driving perform-
ance in Parkinson’s disease (J Neurol Neuro-
surg Psychiatry 2005;76:176–80). SD instead of
SE was inadvertently inserted during the
publication process in tables 2, 3, and 4. The
p values are unaffected.
doi: 10.1136/jnnp.2003.029389corr1
Barber PA, Demchuk AM, Hill MD, et al. The
Probability of middle cerebral artery MRA
flow signal abnormality with quantified CT
ischaemic change: targets for future thera-
peutic studies (J Neurol Neurosurg Psychiatry
2004;75:1426–30). The following errors
appeared in this article:
(1) The median CT ASPECTS and DWI
ASPECTS quoted in the article were both
8. These are incorrect and should be CT
ASPECTS 9 and DWI ASPECTS 8;
(2) Sixty-six per cent (95% CI 0.56–0.75) of
the patients had CT ischaemic change,
while 81% (95% CI 0.72–0.88) of the
DWI scans identified areas of hyper-
intense signal (not 67% and 79% quoted
in the article);
(3) In figure 2 the numbers in parentheses
on the x axis were incorrect. The correct
numbers for each ASPECTS value are 10
(34), 9 (21), 8(12), 7 (11), 6 (12), and 5
(10).
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